1. Arterioscler Thromb Vasc Biol
Long-Term Follow-Up Evaluation of Results From Clinical Trial Using Hepatocyte Growth Factor Gene to Treat Severe Peripheral Arterial Disease
by Hirofumi Makino, Motokuni Aoki, Naotaka Hashiya, Keita Yamasaki, Junya Azuma, Yoshiki Sawa, Yasufumi Kaneda, Toshio Ogihara, and Ryuichi Morishita
Arterioscler Thromb Vasc Biol
Volume 32(10):
September 12, 2012
Copyright © American Heart Association, Inc. All rights reserved.

2. Serial changes in parameters.
Serial changes in parameters. A, Changes in ankle-branchial pressure index (ABI). B, Sizes of largest ulcers. C, Rest pain assessed with visual analog scalepain scale (VAS). D, Maximum walking distance. Data are expressed as mean±SD. For comparison between baseline and each time point, data were analyzed using Dunnett test. Asterisks indicate statistically significant. Pre indicates baseline; 2M, 6M, 12M, and 24M indicate 2, 6, 12, and 24 months, respectively, after the second injection; N.S., not significant.
Hirofumi Makino et al. Arterioscler Thromb Vasc Biol. 2012;32:
Copyright © American Heart Association, Inc. All rights reserved.

3. Typical examples of change in ischemic ulcers in patients.
Typical examples of change in ischemic ulcers in patients. The ischemic ulcer in case no.12 was completely healed in 15 months after the second injection. Case no. 3 healed in 24 months. 2 months, 15 months, 24 months indicates 2, 15, and 24 months, respectively, after the second injection. Pre indicates before injection; TAO, thromboangitis obliterans.
Hirofumi Makino et al. Arterioscler Thromb Vasc Biol. 2012;32:
Copyright © American Heart Association, Inc. All rights reserved.